458 related articles for article (PubMed ID: 30046006)
1. CD226 opposes TIGIT to disrupt Tregs in melanoma.
Fourcade J; Sun Z; Chauvin JM; Ka M; Davar D; Pagliano O; Wang H; Saada S; Menna C; Amin R; Sander C; Kirkwood JM; Korman AJ; Zarour HM
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046006
[TBL] [Abstract][Full Text] [Related]
2. Recovery of CD226-TIGIT
Long Y; Wang C; Xia C; Li X; Fan C; Zhao X; Liu C
Immunol Lett; 2020 Feb; 218():30-39. PubMed ID: 31883787
[TBL] [Abstract][Full Text] [Related]
3. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
Fuhrman CA; Yeh WI; Seay HR; Saikumar Lakshmi P; Chopra G; Zhang L; Perry DJ; McClymont SA; Yadav M; Lopez MC; Baker HV; Zhang Y; Li Y; Whitley M; von Schack D; Atkinson MA; Bluestone JA; Brusko TM
J Immunol; 2015 Jul; 195(1):145-55. PubMed ID: 25994968
[TBL] [Abstract][Full Text] [Related]
4. Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.
Deng C; Li W; Fei Y; Wang L; Chen Y; Zeng X; Zhang F; Li Y
Front Immunol; 2020; 11():1619. PubMed ID: 32793241
[TBL] [Abstract][Full Text] [Related]
5. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
6. CD226 attenuates Treg suppressive capacity via CTLA-4 and TIGIT during EAE.
Wang N; Liang S; Jin J; Fang L; Ma Q; Wang X; Song Y; Chen L
Immunol Res; 2019 Dec; 67(6):486-496. PubMed ID: 31919790
[TBL] [Abstract][Full Text] [Related]
7. Alteration of CD226/TIGIT immune checkpoint on T cells in the pathogenesis of primary Sjögren's syndrome.
Deng C; Chen Y; Li W; Peng L; Luo X; Peng Y; Zhao L; Wu Q; Zhang W; Zhang X; Fei Y
J Autoimmun; 2020 Sep; 113():102485. PubMed ID: 32466852
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
[TBL] [Abstract][Full Text] [Related]
9. The TIGIT/CD226 axis regulates human T cell function.
Lozano E; Dominguez-Villar M; Kuchroo V; Hafler DA
J Immunol; 2012 Apr; 188(8):3869-75. PubMed ID: 22427644
[TBL] [Abstract][Full Text] [Related]
10. Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients.
Li C; Liu H; Duan Z
BMC Immunol; 2024 Feb; 25(1):12. PubMed ID: 38326745
[TBL] [Abstract][Full Text] [Related]
11. CD8
Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
[TBL] [Abstract][Full Text] [Related]
12. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
13. Human CD4
Šunina M; Alnek K; Kisand K; Uibo R
Scand J Immunol; 2021 Sep; 94(3):e13089. PubMed ID: 35971920
[TBL] [Abstract][Full Text] [Related]
14. Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis.
Li W; Deng C; Yang H; Lu X; Li S; Liu X; Chen F; Chen L; Shu X; Zhang L; Liu Q; Wang G; Peng Q
Arthritis Res Ther; 2021 Jan; 23(1):15. PubMed ID: 33413573
[TBL] [Abstract][Full Text] [Related]
15. CD226
Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
[TBL] [Abstract][Full Text] [Related]
16. Decrease in CD226 expression on CD4
Li C; Zhou J; Shao J; Yuan L; Cheng Q; Wang L; Duan Z
Biosci Trends; 2023 May; 17(2):168-171. PubMed ID: 37081668
[TBL] [Abstract][Full Text] [Related]
17. Enhanced expression of TIGIT but not neuropilin-1 in patients with type 2 diabetes mellitus.
Hoseini-Aghdam M; Sheikh V; Eftekharian MM; Rezaeepoor M; Behzad M
Immunol Lett; 2020 Sep; 225():1-8. PubMed ID: 32540486
[TBL] [Abstract][Full Text] [Related]
18. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
19. TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit.
Pauken KE; Wherry EJ
Cancer Cell; 2014 Dec; 26(6):785-787. PubMed ID: 25490444
[TBL] [Abstract][Full Text] [Related]
20. The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy.
Arruga F; Rubin M; Papazoglou D; Iannello A; Ioannou N; Moia R; Rossi D; Gaidano G; Coscia M; Laurenti L; D'Arena G; Allan JN; Furman RR; Vaisitti T; Ramsay AG; Deaglio S
Haematologica; 2023 Aug; 108(8):2101-2115. PubMed ID: 36655432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
